Taysha Gene Therapies (NASDAQ:TSHA) Receives "Overweight" Rating from Cantor Fitzgerald

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report)'s stock had its "overweight" rating reissued by stock analysts at Cantor Fitzgerald in a note issued to investors on Monday,Benzinga reports. They presently have a $7.00 price objective on the stock. Cantor Fitzgerald's target price would suggest a potential upside of 171.32% from the company's current price.

Other analysts also recently issued reports about the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $6.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, April 10th. Chardan Capital reissued a "buy" rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a report on Wednesday, February 26th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Taysha Gene Therapies has an average rating of "Buy" and a consensus target price of $6.63.

Taysha Gene Therapies Stock Performance

Shares of NASDAQ TSHA traded up $0.17 during midday trading on Monday, hitting $2.58. The company's stock had a trading volume of 5,758,382 shares, compared to its average volume of 2,742,524. The stock has a fifty day moving average price of $1.59 and a 200 day moving average price of $1.80. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48. Taysha Gene Therapies has a one year low of $1.05 and a one year high of $4.32. The firm has a market capitalization of $529.04 million, a price-to-earnings ratio of 4.10 and a beta of 0.96.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.08) by $0.01. The company had revenue of $2.02 million for the quarter, compared to analyst estimates of $2.05 million. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. On average, research analysts forecast that Taysha Gene Therapies will post -0.35 EPS for the current fiscal year.

Institutional Investors Weigh In On Taysha Gene Therapies

Large investors have recently added to or reduced their stakes in the company. Ground Swell Capital LLC purchased a new stake in shares of Taysha Gene Therapies during the fourth quarter worth about $25,000. Cibc World Markets Corp bought a new position in shares of Taysha Gene Therapies during the fourth quarter valued at approximately $28,000. E Fund Management Co. Ltd. purchased a new stake in Taysha Gene Therapies in the fourth quarter worth $31,000. Hsbc Holdings PLC increased its position in Taysha Gene Therapies by 65.6% during the 4th quarter. Hsbc Holdings PLC now owns 20,391 shares of the company's stock valued at $36,000 after purchasing an additional 8,076 shares during the period. Finally, AXQ Capital LP bought a new position in Taysha Gene Therapies in the 4th quarter worth $39,000. Institutional investors own 77.70% of the company's stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.